NanoViricides (OTCBB:NNVC) Monday announced that Stanley Glick has been appointed as a director of the company and the chairman of its audit committee.
has over forty years of experience in his long career of providing
auditing, accounting, tax, and management advisory services, to clients
in various industries. He has been a member of several boards of
directors for not-for-profit organizations in the Westport, Connecticut
Glick is also a member of the American Institute of
Certified Public Accountants, The Connecticut Society of Certified
Public Accountants, and the New York State Society of Certified Public
He holds a Bachelor of Business Administration
degree in Accounting from Baruch College of Business (now Baruch College
of the City University of New York).
"Stanley’s broad business, accounting and auditing experience will be very helpful to us," NanoViricides president Anil R. Diwan said.
CEO & CFO Eugene Seymour added: "With the appointment of Stanley as
an independent director and audit committee chairman, we are now able
to significantly improve the Company’s financial oversight and
NanoViricides is a development-stage company that is creating special purpose nanomaterials for viral therapy.
company's novel nanoviricide class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle them.
is developing drugs against a number of viral diseases including H1N1
swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes keratitis,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.